StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)

Close on Nov 17, 2026Market cap $39.19MP/E –Yield –

Scribe Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-489.8%–
Q2 FY2025Jun 30, 2025-237.4%–

More Scribe Therapeutics figures

See a number that looks wrong?